NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $22 | $11 | $14 | $27 |
| - Cash | $3 | $3 | $4 | $11 |
| + Debt | $0 | $0 | $0 | $2 |
| Enterprise Value | $19 | $8 | $11 | $17 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$10 | -$10 | -$12 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$10 | -$10 | -$12 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.55 | -0.83 | -1.07 | -0.23 |
| % Growth | 33.7% | 22.4% | -365.2% | – |
| Operating Cash Flow | -$10 | -$8 | -$8 | -$2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$10 | -$8 | -$8 | -$2 |